Fig. 1
From: Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis
Study design. A Pathological images of the liver with Masson trichrome staining. Control mice showed no fibrosis. After 8 weeks of CCl4 administration, slight bridging fibrosis was observed between the portal area (preliminary experiment). After 12 weeks of CCl4 administration, bridging fibrosis was more significant and showed the Desmet-Scheuer scoring Stages 2–3. Rifaximin treatment for 2 weeks did not improve the fibrosis. B Mice in the control group were treated with corn oil and Tween-80. Mice in the CCl4 group were treated with CCl4 and Tween-80. Mice in the rifaximin group were treated with CCl4 and rifaximin. C FITC-dextran gut permeability test. Average and 95% confidence interval are shown. CCl4, carbon tetrachloride. *p < 0.05, compared with the CCl4 group